Inicio › Síndromes mielodisplásicos › Washington › Seattle
Ensayos clínicos de Síndromes mielodisplásicos en Seattle, WA
21 estudios para Síndromes mielodisplásicos buscan participantes en centros de Seattle y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
ReclutandoFase 2
- Swedish Medical Center-First Hill, Seattle
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Collection of Tissue Samples for Cancer Research
ReclutandoEstudio observacional
- Fred Hutchinson, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
ReclutandoFase 1/2
- University of Washington, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
ReclutandoFase 2/3
- Seattle Cancer Care Alliance, Seattle
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
ReclutandoFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ReclutandoFase 1/2
- Seattle Children's Hospital, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
ReclutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
ReclutandoFase 2Se aceptan voluntarios sanos
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
ReclutandoFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
ReclutandoFase 1/2Se aceptan voluntarios sanos
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
ReclutandoFase 1/2
- Fred Hutchinson Cancer Center, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
ReclutandoFase 2
- Fred Hutchinson Cancer Research Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Más información sobre Síndromes mielodisplásicos en MedlinePlus
Ensayos de Síndromes mielodisplásicos en otras ciudades
- Houston, TX43 estudios
- Baldwin Park, CA27 estudios
- New York City, NY22 estudios
- Boston, MA20 estudios
- Tampa, FL20 estudios
- Washington, DC19 estudios
- Miami, FL17 estudios
- Durham, NC14 estudios
- Columbus, OH14 estudios
- Atlanta, GA13 estudios
- Chicago, IL13 estudios
- St. Louis, MO13 estudios
Otros estudios en Seattle
- Cáncer de pulmón de células no pequeñas55 estudios
- Cáncer (todos los tipos)48 estudios
- Cáncer de próstata45 estudios
- Leucemia mielógena aguda40 estudios
- Cáncer metastásico39 estudios
- Cáncer de seno37 estudios
- Cáncer del colon y del recto35 estudios
- Cáncer de pulmón34 estudios
- Cáncer de ovario29 estudios
- Cáncer de páncreas22 estudios
- Mieloma múltiple22 estudios
- Leucemia linfoblástica aguda22 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.